Pharvaris N.V. PHVS
As ofNov 20, 2026, 3:25 PM EST
- YTD
- +13.26%
- 1 year
- +29.88%
- Market cap
- 2.22B
- EPS (ttm)
- -3.13
- Shares out
- 70.79M
- Forward P/E
- -10.51
- YTD return
- +13.26%
- 1-year return
- +29.88%
- 50-day average
- 32.95
- 200-day average
- 31.41
- Enterprise value
- 1.95B
- Price / book
- 7.53
- Volume
- 318.73K
- Avg volume
- 757.01K
- Open
- 31.19
- Previous close
- 31.66
- Day's range
- 30.43 – 31.99
- 52-week range
- 23.15 – 43.25
- Beta
- -2.52
- Analysts
- Strong Buy
- Price target
- 58.19 (+85.1%)
- Earnings date
- Apr 1, 2027
Key statistics
- Free cash flow
- -96.46M
- Total cash
- 282.73M
- Total debt
- 603.93K
- Return on equity
- -62.78%
- Short % of float
- 4.35%
Fundamental scorecard
1 of 25 checks passed on PHVS’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health No data
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 40.19
- Target (mean)
- 58.19
- Target (high)
- 78.71
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 1, 2027
Expected Apr 1, 2027. Consensus EPS estimate -0.71282.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 1, 2027 | Mar 30, 2027 | -0.81 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.8134 | -0.77 | +0.04 | +5.34% |
| Aug 12, 2026 | Jun 30, 2026 | -0.7467 | -0.81 | -0.06 | -8.48% |
| May 12, 2026 | Mar 31, 2026 | -0.82187 | -0.70 | +0.12 | +14.83% |
| Apr 2, 2026 | Dec 31, 2025 | -0.71462 | -0.84565 | -0.13 | -18.34% |
| Nov 12, 2025 | Sep 30, 2025 | -0.78 | -0.70 | +0.08 | +10.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | up | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | main | Outperform | Outperform |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- pharvaris.com
News
Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High? Pharvaris Q3 EPS $(0.77) Beats $(0.82) Estimate
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on PHVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABELE STEFAN | Chief Operating Officer | Conversion of Exercise of derivative security | Sep 14, 2026 | 39,068 |
| BJORK ELISABETH | Director | Conversion of Exercise of derivative security | Sep 16, 2026 | 15,167 |
| GLASSMAN ROBERT R. | Director | Conversion of Exercise of derivative security | Sep 16, 2026 | 10,500 |
| LESAGE ANNE SIMONNE J PH.D. | Officer | Sale | Sep 16, 2026 | 0 |
| LU PENG | President | Conversion of Exercise of derivative security | Sep 21, 2026 | 110,261 |
| MODIG BERNDT B.A.E | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.58% | 6,921,820 | 219.14M | Sep 29, 2026 |
| Wellington Management Group, LLP | 10.24% | 6,696,804 | 212.02M | Sep 29, 2026 |
| Foresite Capital Management IV, LLC | 7.31% | 4,778,581 | 151.29M | Sep 29, 2026 |
| venBio Partners LLC | 6.82% | 4,458,977 | 141.17M | Sep 29, 2026 |
| Eqt Fund Management S.a R.l. | 5.24% | 3,424,609 | 108.42M | Sep 29, 2026 |
| Viking Global Investors, L.P. | 4.48% | 2,933,310 | 92.87M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.10% | 1,373,193 | 43.48M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.78% | 1,165,414 | 36.90M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.22% | 800,000 | 25.33M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.99% | 644,591 | 20.41M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.61% | 400,000 | 12.66M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.61% | 399,479 | 12.65M | Sep 29, 2026 |
